COST 241213 992.50P (COST241213P992500) Stock Options, News & Quotes

3.48
-14.30-80.43%

15min DelayClose Dec 13 16:00 ET

18.22High0.57Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

10xStockPicks

49 minutes ago

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

10xStockPicks

1 hour ago

Must BUY Esperion Therapeutics Selling FDA Approved Statin Alternative Drugs Will Soon Be Acquired Suspect The Analysts.

SkyHero

Dec 13 08:47

$Costco (COST.US)$ possible 1011 today?

72331255

Dec 13 08:39

$Costco (COST.US)$ hahaha people short Costco is running away.

Cow Moo-ney

Dec 13 07:48

Regaining strength?

Stock futures were higher premarket after markets gave back some recent gains in the previous session. Tech stocks seem to be regaining strength. Let’s see if Nasdaq can close back above the milestone level of 20,000.
Meanwhile, sticky and persistent inflation could force Fed to re-consider their rate cut campaign next year. But that’s for 2025. Next week’s FOMC meeting will likely see the Fed cutting interest rate by 25 basis points again – probably setting the market up for ...

https://youtu.be/XKCRqd1-5go

From YouTube

Fed's year-end meeting: How it will reveal market trends!